Trial Profile
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA-1 or -2 mutated Her2 negative advanced breast cancer as first line treatment (REVIVAL study)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Sep 2021
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Capecitabine; Carboplatin; Eribulin; Paclitaxel; Vinorelbine
- Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer
- Focus Adverse reactions
- Acronyms REVIVAL study
- 06 Jun 2021 This trial has been discontinued in Netherlands, as per European Clinical Trials Database record.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 14 Jan 2019 Status changed from recruiting to completed.